Intranasal desmopressin reduces bleeding risk in CKD patients during non-surgical proceduresDesmopressin may reduce bleeding for some kidney disease patients

Frontiers in Medicine Published August 27, 2026 Study authors: Chananchida Sirilertmekasakul, Porpim Jindasakchai, Sudapree Sorasuchart, Tanat Lertussavavivat, Sur… DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that intranasal desmopressin may significantly reduce bleeding risk in CKD patients undergoing non-surgical procedures.

This meta-analysis evaluated the efficacy of peri-procedural desmopressin to reduce bleeding events in 7,944 adult patients with chronic kidney disease (CKD) undergoing non-surgical procedures. The analysis pooled data from 21 studies to assess primary outcomes including overall bleeding, hematoma, and hematuria, alongside secondary outcomes such as transfusion requirements and hyponatremia.

The meta-analysis found no significant reduction in overall bleeding events (OR 0.87; 95% CI 0.57-1.33), nor were there significant effects for hematoma (OR 1.35; 95% CI 0.40-4.53) or hematuria (OR 1.44; 95% CI 0.50-4.12). However, the analysis identified significant reductions in specific subgroups: randomized controlled trials showed an OR of 0.50 (95% CI 0.29-0.87), and patients receiving desmopressin via the intranasal route showed an OR of 0.52 (95% CI 0.32-0.84).

Clinical application is limited by the lack of significance in the total study population. The findings suggest that while desmopressin may not be universally effective, it may offer a significant reduction in bleeding risk specifically when administered via the intranasal route or within the framework of randomized controlled trials. Safety monitoring for hyponatremia was noted as an assessment point.

How this fits prior evidence

This meta-analysis addresses a gap in managing peri-procedural complications in patients with chronic kidney disease. While previous coverage has discussed various therapeutic targets and potential interventions for renal protection, such as cGAS-STING modulation or cannabinoid receptor targeting, this study specifically evaluates the role of desmopressin in reducing bleeding risks during procedures.

Patients with chronic kidney disease face a serious risk of bleeding during medical procedures. Doctors often look for ways to manage this risk, and one common option is a medication called desmopressin. A large review of 21 studies involving nearly 8,000 patients looked at whether this drug actually helps prevent bleeding.

The overall results were mixed. When looking at all patients combined, the study found that desmopressin did not significantly reduce total bleeding events. It also showed no clear effect on specific issues like hematoma or blood in the urine. However, the data changed when researchers looked closer at specific groups.

Specifically, patients who participated in randomized controlled trials saw a significant reduction in bleeding. Even more specifically, patients who received desmopressin through the nose showed a significant drop in bleeding events. While it is not a universal fix for everyone with kidney disease, these specific methods might offer better protection during procedures.

What this means for you:

Desmopressin may reduce bleeding risk for some kidney patients, especially when given via the intranasal route.

Common questions

Does desmopressin help all patients with kidney disease?

Not necessarily. The study found that desmopressin did not significantly reduce overall bleeding events for all patients with chronic kidney disease. However, it did show a significant reduction in bleeding for patients included in randomized controlled trials and those who received the drug through the nose.

How is this different from other treatments?

While the overall data showed no significant effect on issues like hematoma or blood in the urine, specific delivery methods matter. Patients receiving desmopressin via the intranasal route saw a significant reduction in bleeding events compared to the general group.

Is it safe for patients with kidney disease?

The study monitored for hyponatremia, which is a low level of sodium in the blood. You should talk to your doctor to determine if this specific treatment and delivery method are right for your medical history.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedAug 2026

View Original Abstract ↓

Chronic kidney disease (CKD) is associated with uremic-related platelet dysfunction and a greater risk of perioperative bleeding. Desmopressin (DDAVP) is believed to improve platelet function and is used prophylactically to prevent post-operative bleeding, but with uncertain efficacy. In this research, we evaluated the efficacy of peri-procedural desmopressin administration in reducing bleeding complications in CKD patients. We searched PubMed, Scopus, and Embase up to August 2025 for randomized controlled trials (RCTs) and observational studies involving adult CKD patients undergoing non-surgical procedures who received peri-procedural desmopressin compared to a control group. Outcomes included overall bleeding events, hematoma, hematuria, hematocrit decline, transfusions, and interventions for bleeding control. Safety profile of hyponatremia was also assessed. Of 1,744 records, a total of 7,944 participants from 21 studies were included. The meta-analysis showed that desmopressin did not significantly reduce overall bleeding events (OR 0.87, 95% CI 0.57–1.33). Similarly, there was no significant effect on the incidence of hematoma (OR 1.35, 95% CI 0.40–4.53) or hematuria (OR 1.44, 95% CI 0.50–4.12). Subgroup analysis restricted to randomized controlled trials (RCTs) demonstrated a significant reduction in overall bleeding events with desmopressin (OR 0.50, 95% CI 0.29–0.87). Further subgroup analysis by route of administration revealed that the intranasal route was associated with a significant reduction in total bleeding events (OR 0.52, 95% CI 0.32–0.84). This study suggests that desmopressin does not significantly reduce post-procedural bleeding in CKD patients. However, subgroup analyses restricted to RCTs, and the intranasal administration route suggest a reduction in bleeding complications. PROSPERO ID: CRD420251118342, URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251118342.

Intranasal desmopressin reduces bleeding risk in CKD patients during non-surgical proceduresDesmopressin may reduce bleeding for some kidney disease patients

How this fits prior evidence

Common questions

Study Details

Acupuncture and related therapies improve Pittsburgh Sleep Quality Index scores in post-stroke insomnia

Acupuncture therapies show promise for insomnia after a stroke

Clinical research that matters. Delivered to your inbox.

Intranasal desmopressin reduces bleeding risk in CKD patients during non-surgical proceduresDesmopressin may reduce bleeding for some kidney disease patients

How this fits prior evidence

Common questions

More on Chronic Kidney Disease

Study Details

Acupuncture and related therapies improve Pittsburgh Sleep Quality Index scores in post-stroke insomnia

Acupuncture therapies show promise for insomnia after a stroke

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties